Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines

Autor: Nils Brünner, Anne-Sofie Schrohl, Yves Pommier, Petra Hamerlik, Magnus Stougaard, John A. Foekens, Birgitta R. Knudsen, Signe Lykke Nielsen, José M.A. Moreira, Marcel Smid, Kristina Aluzaite, Stine Ninel Hansen, John W.M. Martens, Madhavsai K. Gajjar, Julie B. Noer, Britt Damsgaard, Haatisha Jandu, Louise Fogh, Khoa Nguyen Do, Jan Stenvang, Joanna Proszek, Sebastian Wingaard Thrane

Publikováno v: Jandu, H, Aluzaite, K, Fogh, L, Thrane, S W, Noer, J B, Proszek, J, Do, K N, Hansen, S N, Damsgaard, B, Nielsen, S L, Stougaard, M, Knudsen, B R, Moreira, J, Hamerlik, P, Gajjar, M, Smid, M, Martens, J, Foekens, J, Pommier, Y, Brünner, N, Schrohl, A-S & Stenvang, J 2016, ' Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines ', BMC Cancer, vol. 16, no. 1, 34 . https://doi.org/10.1186/s12885-016-2071-1
BMC Cancer
Jandu, H, Aluzaite, K, Fogh, L, Thrane, S W, Noer, J B, Proszek, J, Nguyen Do, K, Hansen, S N, Damsgaard, B, Nielsen, S L, Stougaard, M, Knudsen, B R, Moreira, J, Hamerlik, P, Gajjar, M, Smid, M, Martens, J, Foekens, J, Pommier, Y, Brunner, N, Schrohl, A-S & Stenvang, J 2016, ' Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines ', B M C Cancer, vol. 16, no. 1, 34 . https://doi.org/10.1186/s12885-016-2071-1
BMC Cancer, 16:34. BioMed Central Ltd.

Background Studies in taxane and/or anthracycline refractory metastatic breast cancer (mBC) patients have shown approximately 30 % response rates to irinotecan. Hence, a significant number of patients will experience irinotecan-induced side effects w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e5e4ebd0162eaf53b4b940488188f58
https://doi.org/10.1186/s12885-016-2071-1